Interestingly, in orthotopic NSCLC xenografts carrying mutant KRAS/TP53, let-7 and miR-34 have been supplied in combination with erlotinib, an EGFR tyrosine kinase inhibitor, demonstrating a significant synergism that improves treatment efficacy [126]. Here, TP53 is linked to non-small cell lung carcinoma.